Shanghai MicroPort Endovascular MedTech Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Shanghai MicroPort Endovascular MedTech is forecast to grow earnings and revenue by 21.6% and 31.2% per annum respectively. EPS is expected to grow by 19.1% per annum. Return on equity is forecast to be 18.1% in 3 years.
Wichtige Informationen
21.6%
Wachstumsrate der Gewinne
19.1%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 27.5% |
| Wachstumsrate der Einnahmen | 31.2% |
| Zukünftige Eigenkapitalrendite | 18.1% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 01 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
There's No Escaping Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Muted Earnings Despite A 31% Share Price Rise
Oct 01
Earnings Miss: Shanghai MicroPort Endovascular MedTech Co., Ltd. Missed EPS By 16% And Analysts Are Revising Their Forecasts
Aug 29Shanghai MicroPort Endovascular MedTech (SHSE:688016) Will Want To Turn Around Its Return Trends
Aug 15Investors Don't See Light At End Of Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Tunnel
Jun 29These 4 Measures Indicate That Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Using Debt Safely
Apr 29Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Earnings Are Weaker Than They Seem
Apr 09Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Business Is Trailing The Market But Its Shares Aren't
Mar 25Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 2,432 | 1,018 | 563 | 991 | 9 |
| 12/31/2025 | 1,862 | 786 | 360 | 762 | 10 |
| 12/31/2024 | 1,140 | 534 | 279 | 597 | 1 |
| 9/30/2024 | 1,268 | 657 | 390 | 606 | N/A |
| 6/30/2024 | 1,353 | 616 | 437 | 636 | N/A |
| 3/31/2024 | 1,260 | 552 | 458 | 651 | N/A |
| 12/31/2023 | 1,187 | 492 | 368 | 558 | N/A |
| 9/30/2023 | 1,121 | 444 | 166 | 398 | N/A |
| 6/30/2023 | 1,059 | 421 | 22 | 369 | N/A |
| 3/31/2023 | 924 | 358 | -10 | 308 | N/A |
| 12/31/2022 | 897 | 357 | 40 | 334 | N/A |
| 9/30/2022 | 839 | 367 | 133 | 340 | N/A |
| 6/30/2022 | 781 | 346 | 276 | 362 | N/A |
| 3/31/2022 | 745 | 338 | 242 | 337 | N/A |
| 12/31/2021 | 685 | 316 | 211 | 300 | N/A |
| 9/30/2021 | 652 | 302 | 248 | 299 | N/A |
| 6/30/2021 | 618 | 279 | 255 | 291 | N/A |
| 3/31/2021 | 569 | 257 | 239 | 269 | N/A |
| 12/31/2020 | 470 | 215 | 191 | 217 | N/A |
| 9/30/2020 | 414 | 192 | 148 | 174 | N/A |
| 6/30/2020 | 377 | 177 | 142 | 166 | N/A |
| 3/31/2020 | 341 | 156 | 133 | 154 | N/A |
| 12/31/2019 | 334 | 142 | 122 | 143 | N/A |
| 9/30/2019 | 306 | 127 | 117 | 138 | N/A |
| 6/30/2019 | 282 | 115 | 84 | 117 | N/A |
| 3/31/2019 | 257 | 103 | 90 | 118 | N/A |
| 12/31/2018 | 231 | 91 | 82 | 107 | N/A |
| 12/31/2017 | 165 | 63 | N/A | 69 | N/A |
| 12/31/2016 | 125 | 41 | N/A | 30 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 688016's forecast earnings growth (21.6% per year) is above the savings rate (2.9%).
Ertrag vs. Markt: 688016's earnings (21.6% per year) are forecast to grow slower than the CN market (25.8% per year).
Hohe Wachstumserträge: 688016's earnings are expected to grow significantly over the next 3 years.
Einnahmen vs. Markt: 688016's revenue (31.2% per year) is forecast to grow faster than the CN market (14% per year).
Hohe Wachstumseinnahmen: 688016's revenue (31.2% per year) is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 688016's Return on Equity is forecast to be low in 3 years time (18.1%).